GSK (GSK) said Monday that it is partnering with the University of Oxford to investigate cancer prevention through vaccination, with GSK committing up to 50 million British pounds ($62.6 million) in funding over a minimum of three years.
The GSK-Oxford Cancer Immuno-Prevention program will focus on understanding precancer biology to uncover how cancer forms and identify potential vaccine strategies, the organizations said.
GSK's shares were up over 1% in recent Monday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。